Advanced and/or metastatic pancreatic adenocarcinoma.
Conditions
Interventions
Product Name: PBP1510
Product Code: PBP1510
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: PBP1510
Other descriptive name: Anti-(pancreatic adenocarcinoma upregulated
Sponsors
Prestige Biopharma Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients enrolling into Part 1 (Phase 1), or Part 2 (Phase 2a) must meet all of the following inclusion criteria: 1. Adults = 18 years of age (or the legal age of majority in the country of recruitment) at the time consent is obtained 2. Patient should understand, voluntarily sign, and date the written consent form prior to any protocol-specific procedures 3. Performance Status score less than or equal to 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. 4. Have histological or cytological evidence of a diagnosis of pancreatic cancer that is advanced and/or metastatic 5. Have a life expectancy of = 3 months 6. No other malignancy present that would interfere with the current intervention 7. Prior radiation therapy for treatment of cancer is allowed to < 25% of the bone marrow, and patients must have recovered from the acute toxic effects of their treatment prior to study enrolment. Prior radiotherapy must be completed at least 4 weeks before the first dose of study treatment 8. At least one measurable lesion as per RECIST v1.1 9. Adequate baseline organ function defined as: a. Absolute Neutrophil Count = 1.5 × 10^9 /L b. Haemoglobin = 9 g/dL c. Platelets = 100 × 10^9/L d. Total bilirubin = 2 × ULN (= 3 x ULN for patients with biliary stenting) e. AST and ALT < 3 x ULN (= 5 x ULN for patients with hepatic metastases) f. Serum creatinine OR creatinine clearance (as determined by the Cockcroft Gault formula) OR eGFR based on MDRD = 1.5 x ULN OR = 50 mL/min OR = 50 mL/min/1.73 m^2 g. LVEF = 50% by ECHO or MUGA h. QTc = 470 ms 10. Female patients of nonchildbearing potential, must meet at least 1 of the following criteria: have undergone a documented hysterectomy, and/or bilateral oophorectomy; have medically confirmed ovarian failure or achieved postmenopausal status. A postmenopausal state is defined as cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a follicle-stimulating hormone (FSH) level confirming the postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. Female patients of childbearing potential must have a negative serum pregnancy test within 28 days prior to and negative urine pregnancy test just prior to the first dose of PBP1510 and agree to use effective contraception, in accordance with the recommendations of the Clinical Trials Facilitation and Coordination Group (CTFG) from study entry and until for at least 6 months after the last dose of PBP1510 11. For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception (e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) from study entry and until for at least 6 months after the last dose of PBP1510. Investigator or his/her representative should discuss acceptable pregnancy prevention method(s) with the patients. Highly effective methods of birth control include those that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, levonorgestrel-releasing intrauterine system, intrauterine devices (IUD), and true sexual abstinence 12. Patients must be willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guide
Exclusion criteria
Exclusion criteria: Patients enrolling into Part 1 (Phase 1), or Part 2 (Phase 2a) will be excluded if any of the following criteria apply: 1. Patients who have known brain metastases will be excluded from the study. However, a patient may be included in the study, if has been previously treated for brain metastasis, the disease is well controlled for at least 3 months, and the patient is off steroids. 2. Patients who have undergone a major surgery within 4 weeks prior to the start of PBP1510 administration, other than endoscopic/radiation procedures, bypass surgery (e.g., gastrojejunostomy), laparoscopy, port placement or a diagnostic surgery (i.e., surgery done to obtain a diagnostic biopsy, without removal of an organ), as long as the patient has recovered from these minor surgical procedures. 3. Patients who have active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, e.g., an active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii (P. carinii), or other microorganisms that is under treatment with myelotoxic drugs. 4. Patient has a known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies). 5. Patient has known history of or currently active hepatitis B (e.g., hepatitis B antigen [HBsAg] reactive), hepatitis C (e.g., HCV RNA [qualitative] is detected) or syphilis [Venereal Disease Research Laboratory (VDRL) to detect antibodies in blood]). 6. Patient has impaired cardiac function and uncontrolled cardiac diseases/hypertension that are deemed clinically significant by the Investigator and which could compromise the patient’s safety or the study data integrity. 7. Patient has serious psychiatric disorders, which could compromise the patient’s safety or the study data integrity. 8. Any other malignancy from which the patient has been disease-free for less than 5 years, except for adequately treated and cured basal or squamous cell skin cancer. 9. Patients who are enrolled in any other therapeutic clinical trial. 10. Patients currently receiving radiation therapy or those having received radiation within 4 weeks prior to study entry. 11. Patients having received investigational anti-cancer drug within 28 days (or 5 half-lives, whichever is longer) preceding the first dose of PBP1510 or chemotherapy within the last 4 weeks prior to the first dose of PBP1510. 12. Patients with known allergy or hypersensitivity to components of the PBP1510 formulation including the excipients and history of hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies. 13. Patients who are pregnant, or breast feeding. 14. Patients who are unwilling or unable to comply with study procedures. 15. Patients who are not eligible to participate in this study, as judged by Investigators. 16. A history of allergic reactions attributed to gemcitabine or compounds of similar chemical composition to gemcitabine. Note: Patients with previous exposure to gemcitabine should not be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Part 1 In patients with pancreatic cancer whose tumours have progressed after at least one previous line of chemotherapy for locally advanced/metastatic disease, • Evaluate the safety and tolerability of PBP1510 administered as monotherapy, and in combination with gemcitabine Part 2 In patients with pancreatic cancer whose tumours have progressed after one previous line of chemotherapy for locally advanced/metastatic disease, • Establish the safety of PBP1510 administered at the RP2D in combination with gemcitabine • Assess the efficacy of PBP1510 administered at the RP2D in combination with gemcitabine;Secondary Objective: Part 1 • Determine the RP2D of PBP1510 In patients with pancreatic cancer whose tumours have progressed after at least one previous line of chemotherapy for locally advanced/metastatic disease, • Characterize the PK and evaluate the immunogenicity of PBP1510 administered as monotherapy and in combination with gemcitabine • Characterize the PK of gemcitabine administered in combination with PBP1510 Part 1 (Exploratory) Refer to the protocol for the Part 1 exploratory objectives Part 2 In patients with pancreatic cancer whose tumours have progressed after at least one previous line of chemotherapy for locally advanced/metastatic disease, • Characterize the PK of PBP1510 and gemcitabine administered as combination therapy • Evaluate the immunogenicity and additional clinical benefits of PBP1510 administered in combination with gemcitabine Part 2 (Exploratory) Refer to the protocol for the Part 2 exploratory objectives;Primary end point(s): Part 1 In patients with pancreatic cancer whose tumours have progressed after at least one previous line of chemotherapy for locally advanced/metastatic disease, • Safety parameters including adverse events (AE), serious adverse events (SAE), dose-limiting toxicities (DLT), clinical laboratory values (haematology and blood chemistry), vital signs, and electrocardiogram (ECG) assessments in pati | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Part 1 In patients with pancreatic cancer whose tumours have progressed after at least one previous line of chemotherapy for locally advanced/metastatic disease, • Peak concentration (Cmax), the time to reach Cmax (Tmax), terminal elimination half-life (t1/2), area under the concentration-time curve (AUC), mean residence time (MRT), volume of distribution at steady state (Vss), the volume of the central compartment (Vc) and clearance (CL) of PBP1510 administered as monotherapy, and in combination with gemcitabine • Cmax, Tmax, t1/2, AUC, MRT, and CL of gemcitabine administered in combination with PBP1510 • Presence of anti-drug antibody (ADA) and neutralizing antibodies (NAb) against PBP1510 administered as monotherapy, and in combination with gemcitabine Part 1 (Exploratory) In patients with pancreatic cancer whose tumours have progressed after at least one previous line of chemotherapy for locally advanced/metastatic disease, • Preliminary evidence of clinical outcomes as assessed by objective response rate (ORR) after 2 cycles of treatment with PBP1510 administered as monotherapy, and in combination with gemcitabine • Analysis of PAUF in tumour tissue pre-treatment and after 2 cycles of PBP1510 administered as monotherapy, and in combination with gemcitabine, following IV administration, in patients with pancreatic cancer whose tumours have progressed after at least one previous line of chemotherapy for locally advanced/metastatic disease. Part 2 In patients with pancreatic cancer whose tumours have progressed after one previous line of chemotherapy for locally advanced/metastatic disease, • Trough concentration (Ctrough), Cmax, Tmax, t1/2, AUC, MRT, Vss, Vc and CL of PBP1510 administered in combination with gemcitabine • Ctrough, Cmax, Tmax, t1/2, AUC, MRT, and CL of gemcitabine administered in combination with PBP1510 • Progression-free survival (PFS), Overall survival (OS), and duration of response (DoR) after treatment with PBP1510 | — |
Countries
Australia, Belgium, France, Spain, United States
Contacts
Public ContactProject Director
Prestige Biopharma Limited
Outcome results
None listed